ArticleCancers2023

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.

Carole Bandiera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.